SCHEMBL561306

SCHEMBL561306

CCOC(=O)CC(NC(=O)OC(C)(C)C)(C(N)=O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTPRB P23467 1/20 0.37
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CTSK P43235 4/20 0.33
PKM P14618 2/20 0.33
CTSS P25774 2/20 0.33
KDM4E B2RXH2 1/20 0.33
THRB P10828 1/20 0.33
MAOA P21397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560775 0.90 PTPRB (0.42) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL560776 0.90 PTPRB (0.42) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL561889 0.88 HTT (0.44) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL561888 0.88 HTT (0.44) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL561048 0.83 PTPRB (0.45) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL15903847 0.80 CYP1A2 (0.46) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL560931 0.78 ALDH1A1 (0.47) PTPRBMEN1ALDH1A1KMT2A
SCHEMBL560930 0.78 ALDH1A1 (0.47) PTPRBMEN1ALDH1A1KMT2A
SCHEMBL4662942 0.77 PTPRB (0.45) HTTCYP1A2CYP2C9CYP2C19PTPRB
SCHEMBL560683 0.75 ALDH1A1 (0.49) PTPRBMEN1ALDH1A1KMT2ACTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434737-B2 Process for producing optically active succinimide derivatives and intermediates thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-09-06 US disclosed
US-20140099681-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF KYOWA HAKKO BIO CO., LTD. (JP) 2014-04-10 US disclosed
US-8633001-B2 Process for producing optically active succinimide derivatives and intermediates thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-01-21 US disclosed
US-20120034660-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF KYOWA HAKKO BIO CO., LTD. (JP) 2012-02-09 US disclosed
EP-2395097-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVE AND INTERMEDIATE THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140099681-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF SDHA, STS, DHPS HTT 644/4885CYP1A2 276/4885CYP2C9 685/4885
US-20120034660-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF SDHA, STS, ALDH18A1 HTT 870/4885CYP1A2 222/4885CYP2C9 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.